Cellectis S.A. (CLLS) 股票分析

公司概述

Cellectis S.A. operates as a clinical stage biotechnological company dedicated to developing products grounded in gene-editing technologies. The firm focuses on a portfolio of allogeneic chimeric antigen receptor T-cell product candidates within the immuno-oncology sector, alongside gene therapy product candidates for various other therapeutic indications. This company functions within the broader Healthcare sector and specifically the Biotechnology industry, positioning itself as a specialized entity in advanced therapeutic development. Cellectis S.A. currently maintains a market capitalization of $352.07M, reports annual revenue of $79.59M, and employs 224 individuals. These financial scales indicate that the company operates as a mid-sized enterprise within the biotechnology landscape, where market capitalization often reflects high-risk, high-potential asset valuations dependent on future clinical milestones rather than current profitability. The revenue figure of $79.59M suggests a reliance on existing commercial arrangements or licensing deals, while the employee count of 224 points to a lean organizational structure typical for capital-intensive biotech firms in the clinical development phase.

财务健康

Cellectis S.A. reported a revenue of $79.59M over the trailing twelve months, yet it recorded a net income of $-67,593,000 and an EBITDA of $-21,750,000. The substantial gap between the $79.59M revenue and the $-67.59M net income reveals a cost structure heavily weighted toward research and development expenses, where operating costs significantly exceed gross revenues generated. The company generated a free cash flow of $-25,282,376, which indicates a consumption of cash reserves to fund ongoing operations and clinical trials, thereby limiting immediate financial flexibility without external capital raises. Analysis of the three primary margins shows a gross margin of 100.0%, an operating margin of -142.1%, and a profit margin of -84.9%. The 100.0% gross margin implies that the cost of goods sold is negligible relative to sales, likely due to the licensing nature of the revenue or low manufacturing costs for biologics at this stage, while the deeply negative operating and profit margins confirm that overhead and R&D costs are not covered by current earnings. Regarding liquidity, the company holds $206.38M in cash against $86.69M in debt, resulting in a debt-to-equity ratio of 114.22. Although the nominal debt is lower than cash, the high debt-to-equity ratio suggests a leveraged balance sheet structure relative to its equity base, which is common for pre-revenue biotech companies but warrants monitoring. The current ratio stands at 1.62, indicating that the company possesses $1.62 in current assets for every $1 of current liabilities, which points to a reasonably strong short-term liquidity position sufficient to cover near-term obligations. Furthermore, the return on equity is -65.3% and the return on assets is -5.8%, metrics that reveal that management has not yet generated positive returns on the capital invested or deployed, reflecting the long development cycle inherent in the biotechnology sector.

估值评估

The trailing P/E ratio is N/A due to the lack of net income, while the forward P/E is -5.65. The absence of a trailing P/E and the negative forward P/E imply that the market is not valuing the company based on current earnings power but rather anticipates future earnings potential that has not yet been realized. The price-to-book ratio is 3.34, indicating that the market values the company at a premium of 3.34 times its net asset book value, which is typical for biotech firms where intellectual property and pipeline value exceed tangible asset values. Alternative valuation metrics include a price-to-sales ratio of 4.42 and an EV/EBITDA of -6.18, which suggest the market is pricing the stock based on revenue generation and enterprise value multiples rather than profitability, highlighting the speculative nature of the investment. The 52-week high is $5.48 and the 52-week low is $1.17, providing a trading range within which the current price fluctuates based on market sentiment and clinical data releases. The beta value is 2.71, meaning the stock's price volatility is significantly higher than the broader market, rising approximately 2.71 times as much as the market index during upward movements and falling with similar intensity during downturns.

Growth & Income

Cellectis S.A. reported a revenue growth of -19.5% year-over-year, while earnings growth is N/A. The negative revenue growth indicates a contraction in sales, and since earnings are not positive, there is no earnings growth to compare against revenue; this contraction implies a challenging commercial environment or a strategic shift in revenue recognition. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%. This zero payout ratio is sustainable and expected given the negative net income, as the company retains all available capital to reinvest into research, development, and clinical programs rather than distributing returns to shareholders. The overall growth and income profile is characterized by revenue contraction and the absence of dividend income, reflecting the stage of the business where capital retention is prioritized over shareholder distributions or revenue expansion.